US Based Drug Cost Parameter Estimates Using National Average Drug Acquisition Cost

Cost Estimates for National Health Insurance, 1948

,B EFORE the Social Security Board recommended health insurance, it made detailed studies of potential insurance specifications and costs. The results of these studies were made available to the Senate Committee on Education and Labor in 1946 and were the basis of a report published in July of that year? The cost estimates ’ contained in that document were based on late 1945-early 1946 data and...

The cost of drug development.

n engl j med 372;20 nejm.org may 14, 2015 1972 1. Cohen PR. Sweet’s syndrome — a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34. 2. Kroshinsky D, Alloo A, Rothschild B, et al. Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mim­ icking necrotizing fasciitis. J Am Acad Dermatol 2012;67:945­54. 3. Livneh A, Langevitz P, Zemer D...

Economic costs, cost-effectiveness, financing, and community-based drug treatment.

Endogenous Average Cost Based Access Pricing

We consider an industry where a downstream competitor requires access to an upstream facility controlled by a vertically integrated and regulated incumbent. The literature on access pricing assumes the access price to be exogenously ...xed ex-ante. We analyze an endogenous average cost based access pricing rule, where both ...rms realize the interdependence among their quantities and the regula...

Drug-eluting stents: cost versus clinical benefit.

The publication in January 2001 of the first-in-man results showing zero restenosis after sirolimus-eluting stent implantation produced enormous excitement in the cardiological community.1 The long-awaited tool—a safe, restenosis-proof, easy-to-use stent—had been found. It was not too long thereafter that paclitaxel-eluting stents also demonstrated their capability to decrease restenosis. Today...